The Cancer Imaging Shared Resource offers a variety of pre-clinical imaging technologies to image live animal models of cancer. In addition to the broad spectrum of microPET/CT scanners, the shared resource also offers bioluminescence and fluorescence imaging systems, personalized consultations for experimental design and data analysis, and training sessions to provide new users with the skills necessary to meet their cancer research needs. The facility also offers tissue-sectioning facilities, surgery benches, access to ultrasound equipment and optical imaging systems. The shared resource operates under the direction of Timothy C. Doyle, DPhil, who brings years of experience in industry to the operation of the facility. The resource occupies 4180 square feet in four major locations on the Stanford campus and one off-campus, all conveniently located next to animal housing facilities and research laboratories. Three full-time PhD scientists are employed to assist SCI investigators with their imaging needs. The primary imaging facility is located in the Clark Center, and has all the available imaging modalities, including bioluminescence and fluorescence imaging systems, MicroCT scanners, ultrasound and photoacoustic scanners, high-field (7T) MRI, MicroPET/CT and MicroPET scanners, and MicroSPECT/CT scanners. The facility operates on a cost-recovery basis, with ongoing expenses recovered primarily through user fees. The Shared Resource?s annual operating costs are approximately $900,000. Since 2009, over 96 SCI members have used the Shared Resource, with the majority of users coming from the Cancer Imaging and Cancer Stem Cells Programs. Future goals include updating the instruments that are available to users to ensure that the latest technology is available. This includes the replacement of two older MicroSPECT/CT scanners, for which the SCI is contributing resources. The range of imaging modalities in the Lokey barrier imaging facility will also be expanded, since only optical and microPET/CT instruments are currently located in this laboratory.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-13
Application #
9936146
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
13
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications